| Date | Title | | | 11/01/05 | MannKind to Present at Upcoming Healthcare Conferences| CIBC World Markets - November 8, 2005 at 11:00 a.m. (ET) Rodman & Renshaw Techvest - November 9, 2005 at 3:10 p.m. (ET)VALENCIA, Calif., Nov 01, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
two upcoming healthcare conferences: the CIBC World Markets 16th Annual
Healthcare Conference to be held November 7-9, 2005 at ... |
|  | | 10/24/05 | MannKind Corporation Reports Third Quarter Financial Results| Conference Call to Begin Today at 9:00 a.m. ET
VALENCIA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the third quarter and nine
months ended September 30, 2005.
For the third quarter of 2005, total operating expenses were
$32.9 million, compared with $20.5 million for the third quarter of 2004.
Research and development (R&D) expenses increased by $12.7 million to
$24.5 million for the third qua... |
| | | 10/24/05 | MannKind Corporation Announces Addition of Key Executives| VALENCIA, Calif., Oct. 24 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) announced today the addition of several key executives to the
MannKind management team.
Dr. Peter Richardson joins the Company as Corporate Vice President and
Chief Scientific Officer. In this position Dr. Richardson is assuming overall
responsibility for the Company's clinical, regulatory, research and
development activities. For the past 14 years, Dr. Richardson was at
Novartis, where he wa... |
| | | 10/18/05 | MannKind to Present at C.E. Unterberg, Towbin Life Sciences Conference| VALENCIA, Calif., Oct. 18 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the C.E. Unterberg, Towbin Life Sciences Conference to be held October 25-26,
2005 at the Palace Hotel in New York.
Management is scheduled to speak on Tuesday, October 25, 2005 at 1:40 p.m.
Eastern Time (10:40 a.m. PDT) to provide an update on the Company.
Int... |
| | | 10/17/05 | MannKind Corporation to Hold Third Quarter Financial Results Conference Call on October 24, 2005| VALENCIA, Calif., Oct. 17 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2005 third quarter financial results on
Monday, October 24, 2005 at 8:30 a.m. EDT.
Management of the Company will host a conference call to discuss the third
quarter financial results, clinical progress and other Company developments at
9:00 a.m. EDT on Monday, October 24, 2005. Presenting from the Company will
be its Chairman and Chief Executive Officer, Alfred Mann; Presid... |
| | | 09/20/05 | MannKind to Present at UBS 2005 Global Life Sciences Conference| VALENCIA, Calif., Sept 20, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the UBS 2005 Global Life Sciences Conference to be held September 26-29, 2005
at the Grand Hyatt Hotel in New York.
Management is scheduled to speak on Tuesday, September 27, 2005 at 4:00
p.m. Eastern Time (1:00 p.m. PDT) to provide an update... |
| | | 09/02/05 | MannKind Corporation Files Registration Statement For Recently Completed Private Placement| VALENCIA, Calif., Sept. 2 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today filed a registration statement with the Securities and
Exchange Commission covering the resale by certain of its stockholders of 17.1
million shares of common stock issued in a private placement completed on
August 5, 2005 and 3.4 million shares of common stock issuable upon exercise
of warrants also sold in the private placement.
Alfred E. Mann, Chairman of the Board and Chief Executive Off... |
| | | 08/31/05 | MannKind to Present at Oppenheimer Diabetes Conference| VALENCIA, Calif., Aug. 31 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the Oppenheimer Diabetes Conference to be held September 7, 2005, at the
Warwick Hotel in New York City, New York.
Management is scheduled to speak at 3:15 p.m. Eastern Time
(12:15 p.m. PDT) to provide an update on the Company.
Interested parties can access a l... |
| | | 08/22/05 | MannKind Announces Dr. Adrian Bot Appointed Editor-in-Chief of International Reviews in Immunology| VALENCIA, Calif., Aug. 22 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that its Senior Director
of Research and Development, Adrian Bot, M.D., Ph.D. has been appointed
Editor-in-Chief of International Reviews in Immunology, an opinion and
peer-reviewed journal for basic, clinical immunology and immunotherapy,
published by Taylor & Francis Group, a leading internation... |
| | | 08/03/05 | MannKind Corporation Announces $175 Million Private Financing| VALENCIA, Calif., Aug. 3 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) announced today that it has entered into a definitive purchase
agreement for a $175 million private placement of newly issued shares of
common stock and the concurrent issuance of warrants for the purchase of
additional shares of common stock. Leading institutional investors will
invest $87.5 million in the private placement while Alfred E. Mann, Chairman
of the Board, Chief Executive Officer and princi... |
| | | 07/28/05 | MannKind Corporation Reports Second Quarter Financial Results| Company to Review Clinical Trials, Manufacturing Process, and
Financial Outlook on Today's 9:00 a.m. EDT Conference Call
VALENCIA, Calif., July 28 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the second quarter and six
months ended June 30, 2005.
For the second quarter of 2005, total operating expenses were $27.6
million, compared with $18.4 million for the second quarter of 2004. Research
and development (R&D)... |
| | | 07/21/05 | MannKind Corporation to Hold Second Quarter Financial Results Conference Call on July 28, 2005| VALENCIA, Calif., July 21 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) will release its 2005 second quarter financial results on
Thursday, July 28, 2005 at 8:30 a.m. EDT.
Management of the Company will host a conference call to discuss the
second quarter financial results, clinical progress and other Company
developments at 9:00 a.m. EDT on Thursday, July 28, 2005. Presenting from the
Company will be Chairman of the Board and Chief Executive Officer, Alfred E.
Mann... |
| | | 06/29/05 | MannKind Initiates U.S. Pivotal Phase 3 Study of Inhaled Technosphere(R) Insulin| Two-Year Study to Focus on Pulmonary Safety in Patients With
Type 1 and Type 2 Diabetes
VALENCIA, Calif., June 29 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, today announced that it has initiated
patient enrollment in its pivotal phase 3 safety trial of inhaled
Technosphere(R) Insulin (TI) in the United States. The open-label,
randomized, prospecti... |
| | | 06/22/05 | MannKind to Present at 15th Annual Wachovia Securities Nantucket Equity Conference| VALENCIA, Calif., June 22 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today that it will present at
the 15th Annual Wachovia Securities Nantucket Equity Conference to be held
June 27-30, 2005, at the Harbor House Village in Nantucket, Massachusetts.
Management is scheduled to speak on Wednesday, June 29, 2005 at 11:15 a.m.
Eastern Time (8:15 a.m. PDT) to provide an ... |
| | | 06/14/05 | MannKind Presents Safety and Efficacy Data on Inhaled Technosphere(R) Insulin at American Diabetes Association's 65th Scientific Sessions|
- Glucose Lowering Effect Compares Favorably to Conventional Insulin
Injections -
- When Added to Oral Therapy, Patients Achieve Glucose Control With Fewer
Excursions -
VALENCIA, Calif., June 14 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), focused on discovering, developing and commercializing
treatments for diabetes and cancer, announced today additional findings from
two separate studi... |
| | | 06/11/05 | MannKind Reports Inhaled Technosphere(R) Insulin Data at American Diabetes Association's 65th Scientific Sessions| - Mimics the Normally-Occurring First Phase Insulin Response -
- Lowers Post-Meal Glucose Levels Sooner Than Conventional Insulin Injection
and Without Increasing the Risk of Hypoglycemia -
VALENCIA, Calif., June 11 /PRNewswire-FirstCall/ -- New studies presented
today at the 65th annual meeting of the American Diabetes Association in San
Diego, California, highlight the potential of MannKind Corporation's
(Nasdaq: MNKD) lead product, inhaled Technosphere(R) Insulin (TI), t... |
| | | 06/06/05 | MannKind Corporation to Present Data on Inhaled Technosphere(R) Insulin at the American Diabetes Association's 65th Scientific Sessions| VALENCIA, Calif., June 6, 2005 /PRNewswire-FirstCall via COMTEX/ -- MannKind Corporation
(Nasdaq: MNKD), focused on developing and commercializing treatments for
diabetes and cancer, announced today that it will deliver several
presentations at the American Diabetes Association's 65th Scientific Sessions
scheduled for June 10-14, 2005, in San Diego, California. The schedule for
the oral presentations, general poster and poster-discussion sessions is as
follows:
"Mimicry of the Ea... |
| | | 05/16/05 | MannKind Corporation Added to NASDAQ Biotechnology Index| VALENCIA, Calif., May 16, 2005 /PRNewswire-FirstCall via COMTEX/ -- MannKind Corporation
(Nasdaq: MNKD), announced today that it has been selected for addition to the
NASDAQ Biotechnology Index(R) (Nasdaq: NBI).
"MannKind's inclusion in the NASDAQ Biotechnology Index increases our
visibility to the investment community. It is an honor and testament to our
corporate and clinical achievements," stated Hakan Edstrom, President and
Chief Operating Officer of MannKind Corporation.
The... |
| | | 05/06/05 | MannKind Corporation Reports First Quarter Financial Results| Conference Call to Begin Today at 9:00 a.m. EDT
VALENCIA, Calif., May 6 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD) today reported financial results for the three months ended
March 31, 2005.
For the first quarter of 2005, total operating expenses were
$22.6 million, compared with $16.6 million for the first quarter of 2004.
Research and development (R&D) expenses increased by $5.9 million to
$18.7 million, primarily due to increased costs associated with... |
| | | 05/03/05 | MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 6| VALENCIA, Calif., May 3, 2005 /PRNewswire-FirstCall via COMTEX/ -- MannKind Corporation
(Nasdaq: MNKD) will release 2005 first quarter financial results on Friday,
May 6, 2005 at 8:30 a.m. EDT. Following the release, the company will host an
investment community conference call beginning at 9:00 a.m. EDT. Management
will provide a business update and discuss 2005 first quarter financial
results.
To participate in the live call by telephone, please dial (888) 463-4383
from the U.S., ... |
| | | 04/01/05 | MannKind to Present at BioCentury Future Leaders in the Biotech Industry Conference| VALENCIA, Calif., April 1 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), today announced that the company will present at the
BioCentury Future Leaders in the Biotech Industry Conference to be held April
7, 2005 at the Millennium Broadway Hotel and Conference Center in New York
City.
Management is scheduled to speak on Thursday, April 7, 2005 at 11:10 a.m.
Eastern Time (8:10 a.m. Pacific Time) and will provide an update on the
Company.
Interested parties can a... |
| | | 03/18/05 | Henry L. Nordhoff Joins Board of Directors of MannKind Corporation| VALENCIA, Calif., March 18, 2005 /PRNewswire-FirstCall via COMTEX/ -- MannKind Corporation
(Nasdaq: MNKD) today announced that Henry L. Nordhoff has been appointed to
the board of directors of MannKind Corporation and to the board's Compensation
Committee. Mr. Nordhoff's addition brings the board of directors to a total
of nine members.
"Hank's extensive industry experience and insights will serve us very well
as we continue the development activities of MannKind," said Alfred E. Mann... |
| | | 02/03/05 | Mannkind Corporation Reports Fourth Quarter Financial Results| Conference Call to Begin Today at 8:30 a.m. EST VALENCIA, Calif., Feb 03, 2005 /PRNewswire-FirstCall via COMTEX/ -- MannKind Corporation
(Nasdaq: MNKD) today announced financial results for the three months and year
ended December 31, 2004.
For the fourth quarter of 2004 total operating expenses were
$21.7 million, compared with $18.7 million in the fourth quarter of 2003.
Research and development (R&D) expenses increased $6.5 million to
$20.5 million, primarily due to increased costs... |
| | | 01/27/05 | MannKind Corporation to Hold Conference Call Regarding Fourth Quarter Financial Results| VALENCIA, Calif., Jan 27, 2005 /PRNewswire-FirstCall via COMTEX/ -- MannKind Corporation
(Nasdaq: MNKD) will release 2004 fourth quarter financial results on Thursday,
February 3, 2005 before the opening of the financial markets. Following the
release, the company will host an investment community conference call
beginning at 8:30 a.m. EST (5:30 a.m. PST). Management will provide a
business update and discuss 2004 fourth quarter and full year financial
results.
To participate in the... |
| | | 01/26/05 | MannKind to Present at Brean Murray Institutional Investor Conference| VALENCIA, Calif., Jan. 26 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), today announced that the company will present at the Brean
Murray Institutional Investor Conference to be held February 1-2, 2005 at the
New York Palace Hotel in New York City.
Management is scheduled to speak on Wednesday, February 2, 2005 at
10:15 a.m. Eastern Time (7:15 a.m. Pacific Time) and will provide an update on
the Company.
Interested parties can access a link to the live web cas... |
| | | 01/18/05 | MannKind to Present at Piper Jaffray 2005 Health Care Conference| VALENCIA, Calif., Jan. 18 /PRNewswire-FirstCall/ -- MannKind Corporation
(Nasdaq: MNKD), today announced that the company will present at the Piper
Jaffray 2005 Health Care Conference to be held January 25-27, 2005 at the
Pierre Hotel in New York City.
Management is scheduled to speak on Tuesday, January 25, 2005 at 4:00 p.m.
Eastern Time (1:00 p.m. Pacific Time) and will provide an update on the
Company.
Interested parties can access a link to the live web cast of the
presen... |
| |
|
Print | 
E-mail Page | 
RSS Feeds | 
E-mail Alerts | 
IR Contacts | 
Tear Sheet
